MA-to-MA switching among dually eligible beneficiaries rose sharply from 2016 to 2022, AJMC study author Grace Mackleby, PhD, found.

CAR T-cell therapy must be treated as a complete "vein-to-vein" episode, with community practices needing to take control of cases for a period of time.

Aligning financial incentives with patient-centered care is becoming an increasingly complex path to navigate within oncology.

Phase 3 wins for ianalumab and dazodalibep bring targeted therapies closer for Sjögren disease as patients face diagnostic delays and high costs.

New data on atopic dermatitis show treatment gaps, heavy reliance on dermatology APPs, and wide state variation in specialist supply

FDA accepted United Therapeutics' sNDA for inhaled treprostinil in IPF. Here's what it could mean for patient access, coverage, and costs

Average stand-alone Part D premiums are projected to rise by less than $1 a month as a temporary subsidy program ends after 2026.

A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.